Weekly Bortezomib Administration in Daratumumab‑VRD Regimens

Dosing Schedule Recommendations

• The NCCN guideline recommends using a weekly bortezomib schedule (days 1, 8, 15 of each 4‑week cycle) after the initial induction cycles to minimize cumulative peripheral‑neuropathy risk. 1
• For patients with pre‑existing neuropathy or high neuropathy risk, the NCCN guideline advises starting weekly bortezomib from cycle 1 rather than the twice‑weekly schedule. 1
• Transition to weekly bortezomib is suggested beginning with cycle 5 onward for newly diagnosed patients, after an initial intensive twice‑weekly phase (days 1, 4, 8, 11) to achieve maximal early disease control. 1

Efficacy (Comparative Outcomes)

• Weekly bortezomib achieves comparable efficacy to the twice‑weekly schedule, with no statistically significant difference in median PFS or OS. 1

Safety and Tolerability

• Weekly dosing markedly lowers peripheral‑neuropathy incidence (≈ 18.5 % vs 34.7 % with twice‑weekly). 1
• Grade 3/4 adverse events are less frequent with weekly dosing (37 %/3 % vs 48 %/12 % for dose reductions and severe toxicities, respectively). 1
• In relapsed/refractory patients, weekly bortezomib is associated with a low grade 2‑3 peripheral‑neuropathy rate of about 7 %. 1
• Subcutaneous administration of bortezomib is strongly preferred over intravenous delivery, providing non‑inferior efficacy while significantly reducing neuropathy risk. 1

Implementation Trends

• Utilization of weekly bortezomib increased from roughly 58 % of patients in 2017 to 73 % in 2022, reflecting growing clinical preference for the safer schedule. 1

Supportive Care and Monitoring

• Mandatory herpes‑zoster prophylaxis is required for all patients receiving proteasome inhibitors, per Blood‑published recommendations. 2
• When carfilzomib is substituted for bortezomib, close monitoring for cardiac, renal, and pulmonary toxicities is advised (NCCN guideline). 1

Guideline Summary for Daratumumab‑VRd Regimen in Multiple Myeloma

Bortezomib Dosing in Cycle 1

• Administer bortezomib 1.3 mg/m² subcutaneously on days 1, 4, 8, and 11 of the first 4‑week cycle; this twice‑weekly schedule is maintained throughout cycle 1. 3

Lenalidomide Dosing in Cycle 1

• Give lenalidomide 25 mg orally once daily on days 1–14 of the first 4‑week cycle. This differs from the traditional 3‑week VRd schedule, where lenalidomide is also given on days 1–14 but within a 21‑day cycle. 3

Dexamethasone Administration Options

• Option 1: 20 mg dexamethasone on the day of and the day after each bortezomib dose. 3
• Option 2: 40 mg dexamethasone on days 1, 8, 15, and 22 of the 4‑week cycle. 3

Cycle Structure Comparison (VRd vs. Dara‑VRd)

• Standard VRd without daratumumab uses 3‑week cycles with bortezomib administered on days 1, 8, and 15 only; adding daratumumab converts the regimen to 4‑week cycles with a more intensive bortezomib schedule (days 1, 4, 8, 11) during the first eight cycles. 3

Pre‑medication Prior to Daratumumab Infusion

• Administer 20 mg dexamethasone (IV or oral) 1–3 hours before each daratumumab infusion. 4
• Provide an antihistamine (oral or IV) 1–3 hours before infusion. 4
• Give an antipyretic (acetaminophen 650–1000 mg orally) 1–3 hours before infusion. 4

Safety: Peripheral Neuropathy Risk

• The twice‑weekly bortezomib schedule in the first 1–2 weeks of each cycle is associated with an increased risk of peripheral neuropathy. 5
• Grade ≥ 2 peripheral neuropathy was reported in 27 % of patients receiving weekly subcutaneous bortezomib combined with isatuximab‑VRd, highlighting the need for monitoring when similar dosing is used. 5

Frontline Daratumumab‑VRd Quadruplet Therapy for Newly Diagnosed Multiple Myeloma

Maintenance Therapy

Treatment Duration

Patient‑Specific Strategies

Guideline Recommendations

Evidence Level